"Men"

Cervical cancer is one of the most common gynecological malignancies. Its incidence rate is second only to endometrial cancer worldwide, and it ranks first in developing countries and regions. According to statistics, there are 450000 new cases of cervical cancer worldwide every year. The occurrence and development of cervical cancer usually go through a relatively long process, so it is possible to prevent this disease.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

To prevent dry skin, roughness and constipation, you should also pay attention to diet and nutrition. Vitamin A has the role of promoting epithelial growth and protecting the skin, so eat more carrots and green leafy vegetables and beans containing vitamin A in autumn.

This is the best way to prevent blood clots.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

Approval for new FIC depression drug on the horizon!

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!